What is Circular Genomics?
Circular Genomics is at the forefront of precision medicine, pioneering a novel approach using circular RNA to enhance the diagnosis and treatment of psychiatric and neurological disorders. Their flagship product, MindLight, is a groundbreaking antidepressant response test that leverages brain-derived biomarkers to predict patient responses to SSRI antidepressant treatments. This innovation aims to streamline the selection process for mental health treatments, ultimately improving patient outcomes and fostering a deeper understanding of brain conditions. The company's focus on circular RNA biomarkers positions it as a key player in the evolving landscape of mental health diagnostics and therapeutics.
How much funding has Circular Genomics raised?
Circular Genomics has raised a total of $28.1M across 4 funding rounds:
Angel/Seed
$4.5M
Series A
$8.3M
Other Financing Round
$250K
Series A
$15M
Angel/Seed (2021): $4.5M, investors not publicly disclosed
Series A (2024): $8.3M led by Cottonwood Technology Fund, Tramway Venture Partners, UNM Rainforest Innovations, and Mountain Group Partners
Other Financing Round (2025): $250K supported by Alzheimer's Drug Discovery Foundation
Series A (2025): $15M featuring Alzheimer's Drug Discovery Foundation, Mountain Group Partners, and Poplar Grove Investments
Key Investors in Circular Genomics
Cottonwood Technology Fund
Cottonwood Technology Fund is an early-stage venture capital fund specializing in patent-based hard science and deep tech startups, with a focus on health sciences and enabling technologies.
Tramway Venture Partners
Tramway Venture Partners is a life sciences investment firm focused on building disruptive companies within the life sciences sector, particularly in less conventional locations.
UNM Rainforest Innovations
UNM Rainforest Innovations is a nonprofit organization dedicated to commercializing technologies developed at the University of New Mexico, fostering innovation and economic development.
What's next for Circular Genomics?
With the recent influx of major strategic investment, Circular Genomics is poised for significant expansion and further innovation. This capital infusion, likely a Series A round given the context, will enable the company to scale its operations, enhance its research and development capabilities, and potentially broaden the application of its MindLight test. The company's strategic focus on leveraging circular RNA for neurological and psychiatric disorders suggests a trajectory towards becoming a leader in personalized mental healthcare. Future developments may include expanding the biomarker panel, pursuing regulatory approvals, and forging strategic partnerships within the healthcare and pharmaceutical industries to bring their advanced diagnostic solutions to a wider patient population.
See full Circular Genomics company page
